Press Release

August 13, 2026 The Manager Listing Department, The National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 Dear Sir/Madam, Trading Symbol: ZOTA Sub: Press Release on Unaudited Financial Results for the quarter ended June 30, 2026 With reference to the captioned subject; we, M/s Zota Health Care Limited, are forwarding herewith enclosed a copy of press release on Unaudited Financial Results for the quarter ended June 30, 2026. This is for your information and record. Thanking you, Yours faithfully, For Zota Health Care Limited Ashvin Variya (Group Company Secretary & Compliance Officer) Place: Surat Encl.: Press Release Registered Office: Zota House, 2/896, Hira Modi Street, Sagrampura, Surat-395002 Ph: +91 261 2331601 Email: info@zotahealthcare.com Web: www.zotahealthcare.com CIN: L24231GJ2000PLC038352 ress Release – Q2FY22 PRESS RELEASE Q1FY27 Zota Health Care Limited Commences FY27 with Strong expansion adding with 264 New Store Additions Q1FY27 Consolidated Revenues Grew by 67.59% YoY to ₹17,360.23 lakhs Davaindia Networks Expands to 2,825 Stores Nationwide Surat, August 13, 2026: Zota Health Care Limited, one of the leading pharmaceutical Company with an aim to provide affordable, high-quality, generic medicines predominantly for chronic conditions, in addition to proprietary medicinal, OTC, ayurvedic, cosmetic, and nutraceutical products, announced financial results for the first quarter ended June 30, 2026. Q1FY27 Consolidated Financial Snapshot Quarter Ended Year ended Particulars (₹in Lakhs) Q1FY27 Q4FY26 Q1FY26 FY26 FY25 Export Sales (SEZ) 573.51 801.15 664.16 3,471.09 3,190.34 Davaindia Sales 14,342.33 13,147.71 7,562.90 41,741.47 18,621.40 Domestic Sales 1,790.67 1,919.70 1,506.87 6,794.29 6,341.50 Everyday Herbal Group 649.42 443.41 624.41 1,846.33 1,144.22 Others 4.30 5.56 - 12.57 - Revenue from Operations 17,360.23 16,317.53 10,358.34 53,865.75 29,297.48 Gross Profit 10,756.00 10,355.82 5,845.07 32,468.90 15,567.15 Gross Margin % 61.96% 63.46% 56.43% 60.28% 53.13% EBITDA -955.40 1,191.17 483.35 2,597.73 366.49 EBITDA Margin% - 7.30% 4.67% 4.82% - As on 30th June 2026 Q1FY27 Operational Metrics Snapshot Q1FY27 Q1FY26 Particulars COCO FOFO Total COCO FOFO Total Total No. of Davaindia stores* 1,855 970 2,825 986 759 1745 Quarterly Footfall (lakhs) 44.19 15.81 60.00 22.95 12.4 35.35 Quarterly GMV (₹ lakhs) ₹ 11,569 ₹ 4,833 ₹ 16,402 ₹ 5,290 ₹ 3,488 ₹ 8,778 Average wallets spend (₹) ₹ 262 ₹ 306 - ₹ 231 ₹ 281 - As on 30th June 2026 Key Business Highlights: • Davaindia Sales stood at ₹17,360.23 lakhs in Q1FY27, compared to ₹10,358.34 lakhs in Q1FY26, registering a YoY growth of 67.59%, driven by network expansion and healthy demand across existing stores. • Added 264 new stores during Q1FY27 with 201 COCO & 63 FOFO stores. • Closed 18 stores during Q1FY27 with 2 COCO & 16 FOFO stores. • Acquired of 39,794 equity shares of wholly owned subsidiary Davaindia Health Mart Limited through a rights issue, reinforcing the Company's commitment to scaling its retail healthcare platform. • Appointed Mr. Akshay Kumar as the Brand Ambassador for Zota Health Care and UGO Generic, aimed at enhancing brand visibility and strengthening consumer engagement nationwide. ZOTA HEALTHCARE LIMITED | WWW.ZOTAHEALTHCARE.COM | Q1FY27 RELEASE | PAGE 1 OF 2 ress Release – Q2FY22 PRESS RELEASE Q1FY27 • Company continued to strengthen its healthcare ecosystem through strategic investments in subsidiaries, including investments in KMHP Ventures Limited and Curexis Ventures Private Limited, to support the expansion of the UGO Generic and SKIA retail formats. • Acquired an 80% stake in Globotask IT Consultancy Services Private Limited, supporting the development of digital capabilities and technology infrastructure across its businesses. Commenting on the FY26 performance, Mr. Ketan Kumar Zota, Chairman, Zota Health Care Limited said, “We are pleased to begin FY27 on a strong note, building on the strong execution delivered during FY26. During the previous year, we successfully achieved the key milestones we had guided for, including robust revenue growth, expansion of the Davaindia network, improved profitability, and strengthening of our healthcare ecosystem. The momentum continued into Q1FY27, with the Davaindia network expanding to 2,825 stores as of June 30, 2026, supported by the addition of 264 stores during the quarter, further strengthening our nationwide presence and reinforcing the growing acceptance of our affordable healthcare model. Alongside network expansion, we continued to take strategic steps to deepen our presence across the healthcare and consumer wellness value chain. During the quarter, the Company strengthened its investment in Davaindia Health Mart Limited and continued to support growth platforms such as UGO Generic and SKIA through investments in KMHP Ventures Limited and Curexis Ventures Private Limited. Further, our enhanced stake in Everyday Herbal Beauty Care Limited supports our backward integration strategy. The association with Mr. Akshay Kumar as Brand Ambassador for Zota Health Care and UGO Generic also marks an important step towards enhancing brand visibility and consumer engagement at a national level. As we move ahead, our focus remains on sustainable and disciplined growth. While the long-term opportunity in affordable generic medicines continues to remain significant, we intend to moderate the pace of expansion during Q2FY27 and closely observe operating trends across newly added stores. This will allow us to assess store-level performance, improve productivity, and strengthen execution before the next phase of expansion. With a strong foundation, expanding retail network, improving brand recall, and a clear roadmap for growth, we remain confident of building on the achievements of FY26 and continuing our growth journey in FY27.” About Zota Health Care Limited: Zota Health Care Ltd. (Zota), listed on the NSE, has been a key player in the Indian healthcare industry since 2000. Headquartered in Surat, Zota's team of over 620 professionals drives its growth and strong market presence. The company specializes in the development, manufacturing, and marketing of high-quality pharmaceutical, ayurvedic, nutraceutical, and over-the-counter products. Zota operates through three main divisions: marketing, export, and the retail pharmacy chain. In 2017, Zota launched Davaindia, a generic pharmacy chain offering over 2,000 SKUs of quality medicines. Davaindia's strategic business model ensures efficient management of the entire product life cycle through backward and forward integration. Zota is renowned for its innovative Research and Development team, consistently investing in pioneering healthcare solutions, reinforcing its reputation in the industry. For more information, visit: www.zotahealthcare.com For details please contact: Ashvin Variya Siddesh Chawan Ajit Mishra Group Company Secretary & Compliance Officer Ernst & Young LLP, Ernst & Young LLP, Zota Health Care Ltd Investor Relations Investor Relations E: cszota@zotahealthcare.com E: Siddesh.Chawan@in.ey.com E: Ajit.J.Mishra@in.ey.com Disclaimer: Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political, or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Zota Health Care Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances. ZOTA HEALTHCARE LIMITED | WWW.ZOTAHEALTHCARE.COM | Q1FY27 RELEASE | PAGE 2 OF 2